© 2000 by Oxford University Press
Journal of the National Cancer Institute, Vol. 92, No. 9, 737-743,
May 3, 2000
© 2000 Oxford University Press
REPORTS |
Joint Effect of Insulin-Like Growth Factors and Mutagen Sensitivity in Lung Cancer Risk
Affiliations of authors: X. Wu, Department of Epidemiology, The University of Texas M. D. Anderson Cancer Center, and School of Public Health, The University of Texas Health Science Center, Houston; H. Yu, Section of Cancer Prevention and Control, Feist-Weiller Cancer Center, Louisiana State University Medical Center, Shreveport; C. I. Amos, M. R. Spitz (Department of Epidemiology), W. K. Hong (Department of Thoracic/Head and Neck Medical Oncology), The University of Texas M. D. Anderson Cancer Center.
Correspondence to: Xifeng Wu, M.D., Ph.D., Department of Epidemiology, Box 189, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030 (e-mail: xwu{at} notes.mdacc.tmc.edu).
Background: We hypothesize that accumulation of genetic damage is dependent on an individual's intrinsic carcinogen sensitivity and on various humoral factors (e.g., insulin-like growth factors [IGFs]) that enhance proliferation, resistance to apoptotic cell death, and clonal outgrowth of genetically damaged cells. We tested this hypothesis by determining whether proliferation potential and genetic instability are associated with the risk of lung cancer. Methods: In a study of 183 lung cancer patients and 227 matched control subjects, we examined the joint effects of latent genetic instability (measured as mutagen sensitivity) and elevated proliferation potential (assessed by measuring IGFs) in lung cancer risk. Levels of IGF-I, IGF-II, and IGF-binding protein-3 (IGFBP-3) in plasma were measured by use of immunoassay kits. Mutagen sensitivity was assessed by quantitating bleomycin- and benzo[a]pyrene diol epoxide (BPDE)-induced chromatid breaks in peripheral blood lymphocyte cultures. Results: Although not statistically significant, the mean levels of IGF-I and the molar ratio of IGF-I/IGFBP-3 were higher in patients with advanced or poorly differentiated disease than in patients with early or well-differentiated disease. Variation in IGFs was not associated with any specific histologic type or tumor stage. High levels of IGF-I and enhanced mutagen sensitivity were individually associated with increased risk of lung cancer: odds ratio (OR) of 2.13 (95% confidence interval [CI] = 1.20–3.78) for IGF-I, 2.50 (95% CI = 1.49–4.20) for bleomycin sensitivity, and 2.95 (95% CI = 1.72–5.06) for BPDE sensitivity. The OR was statistically significantly elevated to 8.88 for both higher IGF-I and bleomycin sensitivity (95% CI = 3.67–21.50) and to 13.53 for higher IGF-I and BPDE sensitivity combined (95% CI = 4.48–40.89). With all three risk factors considered together, the OR was 17.09 (95% CI = 4.16–70.27). High levels of IGFBP-3 alone were associated with reduced lung cancer risk: OR = 0.59 (95% CI = 0.33–1.05). Conclusions: Our data suggest that individuals with genetic instability and higher proliferation potential are at enhanced risk for lung cancer.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Sung, Y.-M. Song, D. A. Lawlor, G. D. Smith, and S. Ebrahim Height and Site-specific Cancer Risk: A Cohort Study of a Korean Adult Population Am. J. Epidemiol., July 1, 2009; 170(1): 53 - 64. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Wu, J. Gu, and M. R. Spitz Mutagen Sensitivity: A Genetic Predisposition Factor for Cancer Cancer Res., April 15, 2007; 67(8): 3493 - 3495. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Wu, J. Gu, Q. Dong, M. Huang, K.-A. Do, W. K. Hong, and M. R. Spitz Joint Effect of Mutagen Sensitivity and Insulin-Like Growth Factors in Predicting the Risk of Developing Secondary Primary Tumors and Tumor Recurrence in Patients with Head and Neck Cancer Clin. Cancer Res., December 1, 2006; 12(23): 7194 - 7201. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. W. Voskuil, A. Vrieling, L. J. van't Veer, E. Kampman, and M. A. Rookus The Insulin-like Growth Factor System in Cancer Prevention: Potential of Dietary Intervention Strategies Cancer Epidemiol. Biomarkers Prev., January 1, 2005; 14(1): 195 - 203. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K M Fong, Y Sekido, A F Gazdar, and J D Minna Lung cancer * 9: Molecular biology of lung cancer: clinical implications Thorax, October 1, 2003; 58(10): 892 - 900. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Mao, S. Pan, S. W. Wen, and K. C. Johnson Physical Activity and the Risk of Lung Cancer in Canada Am. J. Epidemiol., September 15, 2003; 158(6): 564 - 575. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Caporaso The Molecular Epidemiology of Oxidative Damage to DNA and Cancer J Natl Cancer Inst, September 3, 2003; 95(17): 1263 - 1265. [Full Text] [PDF]
|
|
|
|
|
|
X. Wu, G. Tortolero-Luna, H. Zhao, D. Phatak, M. R. Spitz, and M. Follen Serum Levels of Insulin-like Growth Factor I and Risk of Squamous Intraepithelial Lesions of the Cervix Clin. Cancer Res., August 1, 2003; 9(9): 3356 - 3361. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. G. Skinner, D. S. Michaud, G. A. Colditz, E. L. Giovannucci, M. J. Stampfer, W. C. Willett, and C. S. Fuchs Parity, Reproductive Factors, and the Risk of Pancreatic Cancer in Women Cancer Epidemiol. Biomarkers Prev., May 1, 2003; 12(5): 433 - 438. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hurbin, L. Dubrez, J.-L. Coll, and M.-C. Favrot Inhibition of Apoptosis by Amphiregulin via an Insulin-like Growth Factor-1 Receptor-dependent Pathway in Non-small Cell Lung Cancer Cell Lines J. Biol. Chem., December 13, 2002; 277(51): 49127 - 49133. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Spitz, M. J. Barnett, G. E. Goodman, M. D. Thornquist, X. Wu, and M. Pollak Serum Insulin-like Growth Factor (IGF) and IGF-binding Protein Levels and Risk of Lung Cancer: A Case-Control Study Nested in the {beta}-Carotene and Retinol Efficacy Trial Cohort Cancer Epidemiol. Biomarkers Prev., November 1, 2002; 11(11): 1413 - 1418. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Kodama, R. C. Baxter, and J. L. Martin Insulin-Like Growth Factor-I Inhibits Cell Growth in the A549 Non-Small Lung Cancer Cell Line Am. J. Respir. Cell Mol. Biol., September 1, 2002; 27(3): 336 - 344. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Sandhu, D. B. Dunger, and E. L. Giovannucci Insulin, Insulin-Like Growth Factor-I (IGF-I), IGF Binding Proteins, Their Biologic Interactions, and Colorectal Cancer J Natl Cancer Inst, July 3, 2002; 94(13): 972 - 980. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Schoen, J. Schragin, J. L. Weissfeld, F. L. Thaete, R. W. Evans, C. J. Rosen, and L. H. Kuller Lack of Association between Adipose Tissue Distribution and IGF-1 and IGFBP-3 in Men and Women Cancer Epidemiol. Biomarkers Prev., June 1, 2002; 11(6): 581 - 586. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. London, J.-M. Yuan, G. S. Travlos, Y.-T. Gao, R. E. Wilson, R. K. Ross, and M. C. Yu Insulin-Like Growth Factor I, IGF-Binding Protein 3, and Lung Cancer Risk in a Prospective Study of Men in China J Natl Cancer Inst, May 15, 2002; 94(10): 749 - 754. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Xiong, M. L. Bondy, D. Li, H. Shen, L.-E Wang, S. E. Singletary, M. R. Spitz, and Q. Wei Sensitivity to Benzo(a)pyrene Diol-Epoxide Associated with Risk of Breast Cancer in Young Women and Modulation by Glutathione S-Transferase Polymorphisms: A Case-Control Study Cancer Res., December 1, 2001; 61(23): 8465 - 8469. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Lippman and M. R. Spitz Lung Cancer Chemoprevention: An Integrated Approach J. Clin. Oncol., September 15, 2001; 19(90001): 74s - 82. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Ma, E. Giovannucci, M. Pollak, J. M. Chan, J. M. Gaziano, W. Willett, and M. J. Stampfer Milk Intake, Circulating Levels of Insulin-Like Growth Factor-I, and Risk of Colorectal Cancer in Men J Natl Cancer Inst, September 5, 2001; 93(17): 1330 - 1336. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Brognard, A. S. Clark, Y. Ni, and P. A. Dennis Akt/Protein Kinase B Is Constitutively Active in Non-Small Cell Lung Cancer Cells and Promotes Cellular Survival and Resistance to Chemotherapy and Radiation Cancer Res., May 1, 2001; 61(10): 3986 - 3997. [Abstract] [Full Text]
|
|
|
|
|
|
W. K. Hong, M. R. Spitz, and S. M. Lippman Cancer Chemoprevention in the 21st Century: Genetics, Risk Modeling, and Molecular Targets J. Clin. Oncol., November 1, 2000; 18(90001): 9s - 18. [Full Text] [PDF]
|
|
|
|
 |
|
 G. D. Smith, D. Gunnell, and J. Holly Cancer and insulin-like growth factor-I BMJ, October 7, 2000; 321(7265): 847 - 848. [Full Text]
|
|